Development of a Novel Indirect ELISA Assay for the Detection of SARS-CoV-2 IgG antibodies using a Highly sensitive RBD-Nucleoprotein Fusion Antigen

Document Type : Original Articles

Authors

1 Department of Biotechnology. Iranian research organization for science and technology (IROST). Tehran-Iran.

2 Department of Influenza and Other Respiratory Viruses. Pasteur Institute of Iran, Tehran, Iran. ‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬

3 Department of Biotechnology, Iranian Research Organization for Science and Technology (IROST), Tehran, Iran.

10.22092/ari.2024.365446.3084

Abstract

Abstract
Background: The early and accurate diagnosis of COVID-19 is essential for efficient disease management. Traditionally, Enzyme-Linked Immunosorbent Assays for detecting IgG antibodies to SARS-CoV-2 have relied on single antigens, such as the Spike or Nucleoprotein. However, the test sensitivity has not been satisfactory. This study diverges from conventional approaches by developing an indirect ELISA assay utilizing a novel highly-sensitive fusion antigen incorporating both the Receptor-Binding Domain (RBD) and Nucleoprotein (N). The physicochemical characteristics of this unique antigen were examined and confirmed through experimental validation in our recent research. Our primary objective is to augment the diagnostic sensitivity and accuracy of the ELISA assay.
Materials and Method: The indirect ELISA assay was developed using a novel fusion antigen incorporating both the Receptor-Binding Domain (RBD) and Nucleoprotein (N) of SARS-CoV-2. Subsequently, A cohort of 112 patients presenting with COVID-19 symptoms was evaluated to detect SARS-CoV-2 RNA. Additionally, 25 serum samples from pre-pandemic healthy individuals were selected as the negative control group. The study was conducted in Tehran province, Iran, from Murch to July 2022. Serum samples from patients who tested positive using the real-time PCR method were collected, and an in-house indirect ELISA assay was developed. The sensitivity and specificity of the assay were evaluated and compared with the commercial Euroimmun anti-SARS-CoV-2 IgG assay results, which served as the gold standard. The ROC curve was analyzed using GraphPad Prism to assess the accuracy and reliability of the in-house ELISA assay.
Results: The in-house ELISA assay developed in this study demonstrated successful performance and showed 100% sensitivity and 96% specificity in detecting anti-SARS-CoV-2 IgG antibodies. Receiver operating characteristic (ROC) analysis yielded an area under the curve (AUC) of 0.976, indicating high accuracy.
Conclusions: Our in-house ELISA assay exhibits high sensitivity and specificity, highlighting its suitability for commercial development as a reliable diagnostic kit for detecting COVID-19 cases.

Keywords

Main Subjects

Archives of Razi Institute

Articles in Press, Accepted Manuscript
Available Online from 11 November 2024

Files

Share

How to cite

Statistics